A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

NCT02310321 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
FLT3-mutated Acute Myeloid Leukemia

Interventions

DRUG: Gilteritinib
DRUG: Idarubicin
DRUG: Cytarabine

Sponsor

Astellas Pharma Inc